Children born with congenital pulmonary valve disease face a difficult path. The pulmonary valve controls blood flow from the right ventricle to the lungs. When it is malformed or missing, blood can leak backward, forcing the heart to work harder. For decades, the standard fix has been a replacement valve made from animal tissue, implanted during open-heart surgery. But those valves are fixed in size. As a child grows, the valve does not, and that means more operations, often every few years.
That calculus changed on October 1, 2026, when the U.S. Food and Drug Administration approved the Autus Size-Adjustable Valve. The device is a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease. It is the first heart valve designed to be expanded after surgery to keep pace with a child's growth, and the first valve approved in the United States to use polymeric material rather than animal-derived tissue for its leaflets. The approval went to Edwards Lifesciences, which trades on the New York Stock Exchange under the ticker EW. The valve was developed by Autus Valve Technologies Inc.
The valve can be implanted at a diameter as small as approximately 13 millimeters, a size suited to a toddler or preschool-aged child. Later, as the child grows, clinicians can thread a balloon catheter through a blood vessel and widen the valve, eventually reaching up to 22 millimeters, which the FDA describes as comparable to an adult-sized pulmonary valve. Edwards says the expansion is a minimally invasive transcatheter procedure. The hope is fewer open-heart surgeries during childhood.
Congenital heart defects affect about 1 in every 100 U.S. births. According to the CDC, pulmonary valve atresia and stenosis together affect around 4,200 babies in the United States each year. Those numbers frame the stakes. A valve that grows with a child could reshape care for thousands of families.
Key Facts
The FDA announced on October 1, 2026, that it had approved the Autus Size-Adjustable Valve. Acting FDA Commissioner Kyle Diamantas said that children with congenital heart defects who need pulmonary valve replacement have had very limited surgical options, and those options have historically required multiple open-heart surgeries as children grow. Michelle Tarver, M.D., Ph.D., director of the FDA's Center for Devices and Radiological Health, said the Autus Size-Adjustable Valve gives doctors the option of far fewer trips to the operating room, which may result in better quality of life for these children and their families.
The approval rests on a clinical study enrolling 62 pediatric patients across 12 U.S. sites. Eligible ages were 18 months to 16 years. At six-month follow-up, the first 60 patients demonstrated acceptable hemodynamic performance, defined as right-sided blood flow within acceptable limits with no more than mild regurgitation. All patients had a successful procedure. There were no deaths, no blood clots requiring additional treatment, no strokes and no other clot-related complications.
Three patients experienced a fracture in the valve frame, and two patients had reduced movement of one valve leaflet. None of these five events caused symptoms. Two patients began to outgrow the valve, and both had it expanded without surgery, though the FDA described that experience as limited. Edwards reported that 100% of patients were free from device-related complications through 30 days, with no valve reinterventions through six months. Patients will be followed for 10 years.
The review used the premarket approval pathway, the FDA's most stringent Class III device pathway. The valve previously had Breakthrough Device designation, and it is the first pediatric approval from the FDA's Total Product Life Cycle Advisory Program. The pivotal study is listed on ClinicalTrials.gov as NCT05006404, with follow-up planned to February 2036. A new continued-access study, NCT07466745, is also listed.
Traditional replacement valves use animal tissue, which the FDA said tends to harden and break down faster in children, often requiring earlier repeat surgery. The Autus valve instead has leaflets made of a synthetic polymer. This is the first time the agency has approved a valve with polymer leaflets for any use. Boston Children's Hospital, where surgeon Dr. Sophie-Charlotte Hofferberth invented the device, has noted that children currently face invasive replacement surgeries every few years as they grow.
Analysis
The bigger picture here is that the Autus valve shifts the treatment of pediatric pulmonary valve disease from a series of discrete surgical events to a single implant that can be adjusted over time. That is a meaningful change in the care model. Instead of timing each replacement around a child's growth spurt, clinicians can implant a valve early and then widen it with a balloon catheter as needed. The FDA's own language emphasizes that the device may reduce the need for repeat open-heart surgeries.
But the evidence base is still narrow. The pivotal study had no comparison group. Medical Daily reported on October 3 that only two children in the study have needed an expansion so far, and the FDA described that experience as limited. The 62-patient study is small, and the follow-up at six months is short. Frame fractures in three patients and reduced leaflet motion in two patients did not cause symptoms, but they are signals that warrant long-term surveillance. The 10-year follow-up plan is appropriate.
The polymer leaflets are another first. Animal-derived tissue has been the standard for decades, but it tends to harden and fail sooner in children. A synthetic polymer could offer better durability, but it also introduces a new material to the pediatric heart. The FDA's approval of polymer leaflets for any use is a regulatory milestone. Contemporary Pediatrics reported on October 1 that the device is the first valve approved in the U.S. to use polymeric leaflets instead of animal-derived tissue. Whether that translates into fewer reinterventions over a decade will depend on the continued-access study and real-world data.
What this really means is that the approval is a genuine step forward, but it is not a cure-all. The valve still requires open-heart surgery to implant. The expansion procedure is minimally invasive, but it is still a catheterization. And the valve can only be expanded up to 22 millimeters, which is adult size. For a child who reaches that diameter, further growth may again outpace the device. The FDA and Edwards are careful to call the expansion experience limited. That caution is warranted.
Why It Matters
For families, the difference is measured in operating rooms avoided. A child who receives a fixed-size valve may face repeated open-heart surgeries every few years. Each surgery carries risks of infection, bleeding, stroke and long recovery periods. A valve that can be widened with a balloon catheter could spare children those repeated traumas. Dr. Tarver said the option of far fewer trips to the operating room may result in better quality of life for these children and their families.
The numbers underscore the need. Congenital heart defects affect about 1 in every 100 U.S. births. Pulmonary valve atresia and stenosis together affect around 4,200 babies in the United States each year, according to the CDC. For those children, the pulmonary valve is either blocked or missing, and blood flow to the lungs is compromised. A replacement valve is often necessary. The Autus valve offers a new option for those patients.
The approval also matters for the field of pediatric devices. The FDA's Total Product Life Cycle Advisory Program had not previously approved a pediatric device. The Breakthrough Device designation and the premarket approval pathway signal that the agency is willing to prioritize devices for small patient populations. The Priority Review reported on October 1 that the approval went to Edwards Lifesciences and that the valve was developed by Autus Valve Technologies Inc. Edwards Lifesciences, a major structural heart company, now has a first-of-its-kind product in its portfolio. That could encourage further investment in pediatric heart devices, where the market is small and the unmet need is large.
Next Up
The next step is post-market surveillance. Patients in the pivotal study will be followed for 10 years, with follow-up planned to February 2036. The continued-access study, NCT07466745, will gather more data on expansion. Edwards will need to track how the polymer leaflets perform over time and whether frame fractures become more common as the valve is expanded.
Clinicians and families will also watch the expansion experience. Only two patients have needed an expansion so far. As more children grow, the number of expansions will increase, and the real-world durability of the valve will be tested. NovaPharmaNews reported on October 2 that the pivotal study enrolled 62 children at 12 sites in the United States. The FDA's approval is a milestone, but the long-term story is still being written.
Top comments (0)